| 产品描述: | PF-5006739 is a potent and selective inhibitor of CK1δ/ε with IC50s of 3.9 nM and 17.0 nM, respectively. PF-5006739 is a potential therapeutic agent for a range of psychiatric disorders with low nanomolar in vitro potency for CK1δ/ε and high kinome selectivity. PF-5006739 attenuats opioid agent-seeking behavior in a rodent operant reinstatement model in animals in a dose-dependent manner. PF-5006739 improves glucose tolerance in both diet-induced obesity (DIO) and genetic (ob/ob) mice models of obesity. |
| 靶点: |
CK1γ2:3.9 nM (IC50) |
| 体外研究: |
PF-5006739 (10mg/kg/天,皮下注射,每日一次) 显著改善 DIO 小鼠的血糖状况[2]。 |
| 体内研究: |
PF-5006739 对 CK1δ/ε 具有低 nM 体外效力 (IC50 = 3.9 和 17 nM)。 PF-5006739 (0.4-50 μM,5 天) 可在 WAT 组织外植体中快速且剂量依赖性地诱导 mPER2::luc 生物发光。 |
| 参考文献: |
1. Wager TT, et al. Casein kinase 1δ/ε inhibitor PF-5006739 attenuates opioid drug-seeking behavior. ACS Chem Neurosci. 2014 Dec 17;5(12):1253-65. 2. Cunningham PS, et al. Targeting of the circadian clock via CK1δ/ε to improve glucose homeostasis in obesity.Sci Rep. 2016 Jul 21;6:29983. |
| 保存条件: |
-80°C 6个月; -20°C 1个月,避光 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.384 ml |
11.92 ml |
23.841 ml |
| 5 mM |
0.477 ml |
2.384 ml |
4.768 ml |
| 10 mM |
0.238 ml |
1.192 ml |
2.384 ml |
| 50 mM |
0.048 ml |
0.238 ml |
0.477 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |